Pliant Therapeutics, Inc.
PLRX
Rank in Stocks
#22807
Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical... Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avร6 and avร1 integrins, which is currently progressing through three distinct Phase 2a clinical trials. The company's pipeline also includes PLN-1474, a small-molecule selective inhibitor of avร1, which has successfully completed its Phase 1 clinical assessment for treating liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Furthermore, Pliant is nurturing two additional integrin-based initiatives in preclinical development: one focused on oncology, and another involving an allosteric agonistic monoclonal antibody designed to act upon an undisclosed integrin receptor for the treatment of various muscular dystrophies, including Duchenne muscular dystrophy. Founded in 2015, Pliant Therapeutics, Inc. maintains its corporate headquarters in South San Francisco, California.
Share Price
$0.7996
Last synced: 2026-11-09
Market Cap
$49.51M
Change (1 day)
-1.25%
Change (1 year)
-52.12%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Pliant Therapeutics, Inc. (PLRX)
Category
Healthcare
EPS for Pliant Therapeutics, Inc. (PLRX)
EPS as of June 2026 TTM: $-1.49
According to Pliant Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-1.49. At the end of 2025 the company had an EPS of $-2.43, an increase over its 2024 EPS of $-3.47.
EPS history for Pliant Therapeutics, Inc. from 2017 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.49 | -38.68% |
| 2025 | $-2.43 | -29.97% |
| 2024 | $-3.47 | 26.18% |
| 2023 | $-2.75 | -6.46% |
| 2022 | $-2.94 | 8.49% |
| 2021 | $-2.71 | 131.62% |
| 2020 | $-1.17 | 515.79% |
| 2019 | $-0.19 | -89.62% |
| 2018 | $-1.83 | -92.87% |
| 2017 | $-25.67 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -1,151.01% |
US
|
|
| $-7.07 | 374.50% |
US
|
|
| $-5.29 | 255.03% |
AU
|
|
| $12.88 | -964.44% |
BE
|
|
| $21.56 | -1,546.98% |
NL
|
Questions about Pliant Therapeutics, Inc.'s earnings per share (EPS)
What is Pliant Therapeutics, Inc.'s earnings per share (EPS)?
Pliant Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-1.49, as of Jun 2026.
What was Pliant Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Pliant Therapeutics, Inc.'s earnings per share (EPS) was $-2.43, compared with $-3.47 in 2024.
How has Pliant Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Pliant Therapeutics, Inc.'s earnings per share (EPS) was highest in 2020 ($-1.17) and lowest in 2024 ($-3.47).
How does Pliant Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Pliant Therapeutics, Inc.'s earnings per share (EPS) ($-1.49) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.